Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
VICARIOUS SURGICAL INC (RBOT)
OTCHealth CareMedical - DevicesSnapshot 2026-11-04
$0.00-86.49%
Close 2026-11-05 · 1-day change
OTCHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RBOT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain leadership stability after CFO resignation | Leadership is working to stabilize after recent executive changes. | Under Pressure | CFO position remains vacant beyond 2026-Q3 | CFO vacant since 2026-06-24; no successor named CFO Sarah Romano resigned without a successor. The company subsequently approved an assignment for the benefit of creditors and liquidated assets. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
RBOT is a high-risk, loss-making growth business in a Healthcare sector with a supportive backdrop. Its long-term thesis is intact, but confidence is low and recent leadership changes add uncertainty.
The evidence snapshot gives no valuation or market-expectations data, so whether RBOT looks cheap, fair, or expensive versus peers is unclear. The main expectations gap to watch is whether improving cash burn and losses can continue despite leadership turnover.
Near term, management is focused on reducing 2026 cash burn to $19 million and improving financial stability. Cash-burn guidance has been lowered over successive quarters, and reported operating and net losses improved from 2025-Q1 to 2025-Q4, but leadership transitions and rising risk remain concerns.
The thesis depends on management continuing to reduce cash burn and losses while stabilizing leadership. A guidance cut or further weakening in jobs data would add pressure, while strong results and higher guidance from sector bellwethers could support the Healthcare backdrop.
For the next 1 to 3 years, the thesis is intact but fragile: financial improvement is encouraging, while losses, executive departures, and high risk leave execution uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of last 2 quarters. Management disclosed multiple key executive departures including CEO and CFO in 2026-Q2 and Q3. The company is actively managing leadership transitions amid these changes, with mixed progress on stability.
Reduce full-year cash burn to $19 million in 2026 | The company aims to cut cash burn from $50M in 2025 to $19M in 2026. | Intact | cash burn exceeds $19 million in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 3 quarters. Management reduced full-year cash burn guidance from $50 million in 2025-Q3 to $35 million in 2025-Q4, then to $19 million in 2026-Q1. The trajectory shows delivering significant improvement in cash burn reduction. Delivery assessment Oct 19, 2026 |
Reduce operating losses to $9.3 million by 2025-Q4 | Operating losses have improved from $16.1M to $9.3M over eight quarters. | Broken | operating losses exceed $9.3 million in 2025-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 4 of last 4 quarters. Operating losses improved from -$15.7M in 2025-Q1 to -$9.3M in 2025-Q4; net losses improved from -$15.4M to -$10.5M over the same period. Management continues focus on financial stability with a trajectory of gradual improvement. Delivery assessment Oct 19, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.17 → $-2.17 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-07-25 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-07-26 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-07-27 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-07-28 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-07-29 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-07-30 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-07-31 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-01 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-02 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-03 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-04 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-05 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-06 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-07 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-08 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-09 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-10 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-12 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-13 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-14 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-15 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-16 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-17 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-18 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-19 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-20 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-21 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-22 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-23 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-24 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-25 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-26 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-27 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-28 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-29 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-30 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-08-31 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-01 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-02 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-03 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-04 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-05 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-06 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-07 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-08 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-09 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-10 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-11 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-12 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-13 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-14 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-15 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-16 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-17 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-18 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-19 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-20 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-21 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-22 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-23 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-24 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-25 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-26 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-27 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-28 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-29 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-09-30 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-01 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-02 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-03 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-04 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-05 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-06 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-07 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-08 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-09 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-10 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-11 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-12 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-13 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-14 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-15 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-16 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-17 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-18 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-19 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-20 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-21 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-22 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-23 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-24 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-25 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-26 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-27 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-28 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-29 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-30 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-10-31 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-11-01 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-11-02 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-11-03 | $-2.17 | $18,000,000 | 1 / 1 |
| 2026-11-04 | $-2.17 | $18,000,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.